 VANCOUVER, Washington, Sept. 13, 2021 GLOBE NEWSWIRE -- CytoDyn Inc. OTCQB: CYDY CytoDyn or the Company, a late-stage biotechnology company developing leronlimab, a CCR5 antagonist with the potential for multiple therapeutic indications, announced today Nader Pourhassan, Ph.D., President and Chief Executive Officer and Scott Kelly, M.D., Chairman, Chief Medical Officer and Head of Business Development of CytoDyn will provide a comprehensive business update at the upcoming Emerging Growth Conference. CytoDyn will present for 20 minutes, and 40 minutes will be dedicated to live questions and answers. 